A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study

Kathleen N. Moore, Michael W. Sill, David S. Miller, Carolyn McCourt, Koen De Geest, Peter G. Rose, Higinia R. Cardenes, Robert S. Mannel, John H. Farley, Russell J. Schilder, Paula M. Fracasso

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Epithelial growth factor receptor over-expression correlates with poor outcomes in cervical cancer. This study assessed the safety of chemoradiation with cetuximab in the treatment of women with newly diagnosed locally advanced cervical cancer. Methods: Patients received weekly cisplatin 30 and 40 mg/m2 [dose level (DL) 1 and 2] and cetuximab 400 mg/m 2 loading dose and then 250 mg/m2 for a total of six weeks with radiotherapy (RT). Patients with nodal metastases received extended field radiation therapy (EFRT). At the maximum tolerated dose, feasibility was evaluated in a 20 patient two-stage, sequential design. Results: In patients receiving pelvic RT, seven were treated at DL 1 with one dose-limiting toxicity (DLT) (febrile neutropenia with grade 3 diarrhea) and three at DL 2 with two DLTs (grade 3 rash and delay in RT > 8 weeks). The feasibility phase was opened at DL1. Of the 21 patients treated there was one DLT (grade 4 CVA). Median RT duration was 50 days (range, 42-70). In patients receiving EFRT, nine were treated at DL 1 with 1 DLT (grade 3 mucositis) and 24 in the feasibility phase with eight DLTs [delay in RT > 8 weeks due to toxicity (2) and one each with grade 3 or 4 small bowel obstruction, embolism, mucositis, mucositis with hypokalemia, pain with headache, and platelets with mucositis and headache]. Median EFRT duration was 56 days (range, 36-74). Conclusions: For patients receiving pelvic RT, cisplatin and cetuximab were feasible. For patients receiving EFRT, combination of cisplatin and cetuximab was not feasible.

Original languageEnglish (US)
Pages (from-to)456-461
Number of pages6
JournalGynecologic Oncology
Volume127
Issue number3
DOIs
StatePublished - Dec 2012

Fingerprint

Uterine Cervical Neoplasms
Cisplatin
Radiotherapy
Mucositis
Therapeutics
Headache
Cetuximab
Febrile Neutropenia
Maximum Tolerated Dose
Hypokalemia
Growth Factor Receptors
Exanthema
Embolism
Diarrhea
Blood Platelets
Neoplasm Metastasis
Safety
Pain

Keywords

  • Cervical cancer
  • Cetuximab
  • Pelvic radiation

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer : A gynecologic oncology group study. / Moore, Kathleen N.; Sill, Michael W.; Miller, David S.; McCourt, Carolyn; De Geest, Koen; Rose, Peter G.; Cardenes, Higinia R.; Mannel, Robert S.; Farley, John H.; Schilder, Russell J.; Fracasso, Paula M.

In: Gynecologic Oncology, Vol. 127, No. 3, 12.2012, p. 456-461.

Research output: Contribution to journalArticle

Moore, Kathleen N. ; Sill, Michael W. ; Miller, David S. ; McCourt, Carolyn ; De Geest, Koen ; Rose, Peter G. ; Cardenes, Higinia R. ; Mannel, Robert S. ; Farley, John H. ; Schilder, Russell J. ; Fracasso, Paula M. / A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer : A gynecologic oncology group study. In: Gynecologic Oncology. 2012 ; Vol. 127, No. 3. pp. 456-461.
@article{0a8a0f8e558441b1942ea5456f0edc9d,
title = "A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study",
abstract = "Background: Epithelial growth factor receptor over-expression correlates with poor outcomes in cervical cancer. This study assessed the safety of chemoradiation with cetuximab in the treatment of women with newly diagnosed locally advanced cervical cancer. Methods: Patients received weekly cisplatin 30 and 40 mg/m2 [dose level (DL) 1 and 2] and cetuximab 400 mg/m 2 loading dose and then 250 mg/m2 for a total of six weeks with radiotherapy (RT). Patients with nodal metastases received extended field radiation therapy (EFRT). At the maximum tolerated dose, feasibility was evaluated in a 20 patient two-stage, sequential design. Results: In patients receiving pelvic RT, seven were treated at DL 1 with one dose-limiting toxicity (DLT) (febrile neutropenia with grade 3 diarrhea) and three at DL 2 with two DLTs (grade 3 rash and delay in RT > 8 weeks). The feasibility phase was opened at DL1. Of the 21 patients treated there was one DLT (grade 4 CVA). Median RT duration was 50 days (range, 42-70). In patients receiving EFRT, nine were treated at DL 1 with 1 DLT (grade 3 mucositis) and 24 in the feasibility phase with eight DLTs [delay in RT > 8 weeks due to toxicity (2) and one each with grade 3 or 4 small bowel obstruction, embolism, mucositis, mucositis with hypokalemia, pain with headache, and platelets with mucositis and headache]. Median EFRT duration was 56 days (range, 36-74). Conclusions: For patients receiving pelvic RT, cisplatin and cetuximab were feasible. For patients receiving EFRT, combination of cisplatin and cetuximab was not feasible.",
keywords = "Cervical cancer, Cetuximab, Pelvic radiation",
author = "Moore, {Kathleen N.} and Sill, {Michael W.} and Miller, {David S.} and Carolyn McCourt and {De Geest}, Koen and Rose, {Peter G.} and Cardenes, {Higinia R.} and Mannel, {Robert S.} and Farley, {John H.} and Schilder, {Russell J.} and Fracasso, {Paula M.}",
year = "2012",
month = "12",
doi = "10.1016/j.ygyno.2012.08.030",
language = "English (US)",
volume = "127",
pages = "456--461",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer

T2 - A gynecologic oncology group study

AU - Moore, Kathleen N.

AU - Sill, Michael W.

AU - Miller, David S.

AU - McCourt, Carolyn

AU - De Geest, Koen

AU - Rose, Peter G.

AU - Cardenes, Higinia R.

AU - Mannel, Robert S.

AU - Farley, John H.

AU - Schilder, Russell J.

AU - Fracasso, Paula M.

PY - 2012/12

Y1 - 2012/12

N2 - Background: Epithelial growth factor receptor over-expression correlates with poor outcomes in cervical cancer. This study assessed the safety of chemoradiation with cetuximab in the treatment of women with newly diagnosed locally advanced cervical cancer. Methods: Patients received weekly cisplatin 30 and 40 mg/m2 [dose level (DL) 1 and 2] and cetuximab 400 mg/m 2 loading dose and then 250 mg/m2 for a total of six weeks with radiotherapy (RT). Patients with nodal metastases received extended field radiation therapy (EFRT). At the maximum tolerated dose, feasibility was evaluated in a 20 patient two-stage, sequential design. Results: In patients receiving pelvic RT, seven were treated at DL 1 with one dose-limiting toxicity (DLT) (febrile neutropenia with grade 3 diarrhea) and three at DL 2 with two DLTs (grade 3 rash and delay in RT > 8 weeks). The feasibility phase was opened at DL1. Of the 21 patients treated there was one DLT (grade 4 CVA). Median RT duration was 50 days (range, 42-70). In patients receiving EFRT, nine were treated at DL 1 with 1 DLT (grade 3 mucositis) and 24 in the feasibility phase with eight DLTs [delay in RT > 8 weeks due to toxicity (2) and one each with grade 3 or 4 small bowel obstruction, embolism, mucositis, mucositis with hypokalemia, pain with headache, and platelets with mucositis and headache]. Median EFRT duration was 56 days (range, 36-74). Conclusions: For patients receiving pelvic RT, cisplatin and cetuximab were feasible. For patients receiving EFRT, combination of cisplatin and cetuximab was not feasible.

AB - Background: Epithelial growth factor receptor over-expression correlates with poor outcomes in cervical cancer. This study assessed the safety of chemoradiation with cetuximab in the treatment of women with newly diagnosed locally advanced cervical cancer. Methods: Patients received weekly cisplatin 30 and 40 mg/m2 [dose level (DL) 1 and 2] and cetuximab 400 mg/m 2 loading dose and then 250 mg/m2 for a total of six weeks with radiotherapy (RT). Patients with nodal metastases received extended field radiation therapy (EFRT). At the maximum tolerated dose, feasibility was evaluated in a 20 patient two-stage, sequential design. Results: In patients receiving pelvic RT, seven were treated at DL 1 with one dose-limiting toxicity (DLT) (febrile neutropenia with grade 3 diarrhea) and three at DL 2 with two DLTs (grade 3 rash and delay in RT > 8 weeks). The feasibility phase was opened at DL1. Of the 21 patients treated there was one DLT (grade 4 CVA). Median RT duration was 50 days (range, 42-70). In patients receiving EFRT, nine were treated at DL 1 with 1 DLT (grade 3 mucositis) and 24 in the feasibility phase with eight DLTs [delay in RT > 8 weeks due to toxicity (2) and one each with grade 3 or 4 small bowel obstruction, embolism, mucositis, mucositis with hypokalemia, pain with headache, and platelets with mucositis and headache]. Median EFRT duration was 56 days (range, 36-74). Conclusions: For patients receiving pelvic RT, cisplatin and cetuximab were feasible. For patients receiving EFRT, combination of cisplatin and cetuximab was not feasible.

KW - Cervical cancer

KW - Cetuximab

KW - Pelvic radiation

UR - http://www.scopus.com/inward/record.url?scp=84868530868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868530868&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2012.08.030

DO - 10.1016/j.ygyno.2012.08.030

M3 - Article

C2 - 22960004

AN - SCOPUS:84868530868

VL - 127

SP - 456

EP - 461

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -